Genetic Engineering & Biotechnology News

AbbVie to Acquire Apogee Therapeutics for $10.9B

AbbVie has agreed to acquire Apogee Therapeutics for $10.9 billion, in a deal designed to bolster the buyer’s pipeline with an atopic dermatitis (AD) candidate set to advance to Phase III trials during the second half of this year, and being positioned as a potential challenger to a top-selling drug. Don't miss Alex Philippidis' reporting from BIO.

I am Biotech

AbbVie to Acquire Apogee Therapeutics for $10.9B AbbVie has agreed to acquire Apogee Therapeutics for $10.9 billion, in a deal designed to bolster the buyer’s pipeline with an atopic dermatitis (AD) candidate set to advance to Phase III trials during the second half of this year, and being positioned as a potential challenger to a top-selling dr...

Impact of Early Life Adversity on Epigenome at Molecular Level Mapped in Macaques

The Arizona State University and Vanderbilt University team created highly precise tissue-specific clocks, capable of predicting age within about one year of an individual’s chronological age.

Impact of Early Life Adversity on Epigenome at Molecular Level Mapped in Macaques The team created highly precise tissue-specific clocks, capable of predicting age within about one year of an individual’s chronological age.

Perseverance, Persistence Key to CAR T Success, Say Ross Prize Winners Carl June and Michel Sadelain

The Feinstein Institutes Ross Prize recognizes biomedical scientists whose discoveries have transformed how medicine is practiced. This year's recipients are well known in immunotherapy circles for their efforts to develop CAR T cells now used in cancer therapeutics.

Northwell Health, Perelman School of Medicine at the University of Pennsylvania, Parker Institute for Cancer Immunotherapy, Columbia University Vagelos College of Physicians and Surgeons

Perseverance, Persistence Key to CAR T Success, Say Ross Prize Winners Carl June and Michel Sadelain In separate lectures presented during the award ceremony, both scientists spoke on the many benefits of and future directions for CAR T cells.